Wird geladen...
All-Comers versus Enrichment Design Strategy in Phase II Trials
Designs for biomarker validation have been proposed and utilized in the Phase III oncology clinical trial setting. Broadly speaking, these designs follow either an enrichment (i.e., targeted) strategy or an all-comers (i.e., unselected) strategy. An enrichment design screens patients for the presenc...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2011
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3082391/ https://ncbi.nlm.nih.gov/pubmed/21532916 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31820e17cb |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|